tizanidine NDC 63187-145

NDC codes

FDA NDC Directory

Product NDC (as listed)63187-145Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63187-0145Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
63187-145-30	63187014530	30 TABLET in 1 BOTTLE (63187-145-30)Marketed from Jan 1, 2019
63187-145-60	63187014560	60 TABLET in 1 BOTTLE (63187-145-60)Marketed from Jan 1, 2019
63187-145-90	63187014590	90 TABLET in 1 BOTTLE (63187-145-90)Marketed from Jan 1, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): tizanidine
Generic name (nonproprietary): tizanidine
Active ingredients: Tizanidine hydrochloride — 4 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Proficient Rx LP
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 076533
Marketing start: Jan 16, 2004
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha2-Agonists (Mechanism)
Identifiers: Product ID 63187-145_fa1c80fd-e646-4850-8f31-04c5417978c0SPL ID fa1c80fd-e646-4850-8f31-04c5417978c0SPL set ID cf77e63c-a62a-43fc-8705-0558925e04e8RxCUI 313413UNII B53E3NMY5CUPC 0363187145309
Pharmacologic class: Central alpha-2 Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463187014530 followed by a unit qualifier and the quantity

Package 63187-0145-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 1, 2022.

Indications (excerpt from the label)

INDICATIONS AND USAGE Tizanidine is a short-acting drug for the management of spasticity. Because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see DOSAGE AND ADMINISTRATION ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 076533

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 076533
Product	Strength	Form · route	Labeler	Product NDC
tizanidine	Tizanidine hydrochloride 4 mg/1	TabletOral	Aphena Pharma Solutions - Tennessee, LLC	71610-776
tizanidine	Tizanidine hydrochloride 2 mg/1	TabletOral	Apotex Corp.	60505-0251
tizanidine	Tizanidine hydrochloride 4 mg/1	TabletOral	Apotex Corp.	60505-0252
tizanidine	Tizanidine hydrochloride 4 mg/1	TabletOral	Cardinal Health 107, LLC	55154-7287
tizanidine	Tizanidine hydrochloride 4 mg/1	TabletOral	Preferred Pharmaceuticals Inc.	68788-8741
tizanidine	Tizanidine hydrochloride 2 mg/1	TabletOral	Aphena Pharma Solutions - Tennessee, LLC	71610-455
tizanidine	Tizanidine hydrochloride 4 mg/1	TabletOral	Major Pharmaceuticals	0904-6418